INTRODUCTION
Lymphedema is defined as chronic tissue swelling of soft tissues due to abnormal drainage of lymph by lymphatic vessels [Mortimer, 1995] . Primary lymphedema can be genetic in origin and the most common form of hereditary primary lymphedema is Milroy disease, also known as primary congenital lymphedema (PCL; OMIM #153100). As with most forms of primary lymphedema, Milroy disease has an autosomal dominant mode of inheritance with incomplete penetrance. Milroy disease is usually characterized by bilateral lymphedema of the lower limbs, although unilateral lymphedema has also been reported [Brice et al., 2005] . Other clinical manifestations associated with Milroy disease include hydrocele, large caliber veins, upslanting of the toenail plates known as ''ski jump'' toenails, and papillomatosis of the toes [Brice et al., 2005] .
The only known molecular cause of Milroy disease is mutation in the VEGFR3 gene (formerly FLT-4) [Ferrell et al., 1998; Irrthum et al., 2000; Karkkainen et al., 2000; Evans et al., 2003; Daniel-Spiegel et al., 2005; Mizuno et al., 2005; Ghalamkarpour et al., 2006; Spiegel et al., 2006] . Linkage analysis on Milroy disease families suggests genetic heterogeneity and possibly complex inheritance for Milroy disease although some families clearly have linkage to the VEGFR3 locus on 5q35.3 [Ferrell et al., 1998; Evans et al., 1999; Holberg et al., 2001] . VEGFR3 encodes a receptor tyrosine kinase that is expressed by lymphatic endothelial cells (LECs) [Kaipainen et al., 1995; Partanen et al., 2000] and is activated by the vascular endothelial growth factors VEGF-C and VEGF-D to mediate lymphangiogenesis [Veikkola et al., 2001] . The VEGFR3 gene is composed of 31 exons transcribed as two alternatively spliced transcripts encoding a protein with 7 immunoglobulin-like repeat domains and 2 tyrosine kinase domains [Iljin et al., 2001] . Only 17 VEGFR3 mutations have been identified, and all mutations described localize to one of the two tyrosine kinase domains, illustrating the necessity of these domains in the signal transduction function of VEGFR3 [Ferrell et al., 1998; Irrthum et al., 2000; Karkkainen et al., 2000; Evans et al., 2003; Daniel-Spiegel et al., 2005; Mizuno et al., 2005; Ghalamkarpour et al., 2006; Spiegel et al., 2006] .
In this report, we describe a large family that presented with a form of hereditary lymphedema consistent with Milroy disease. We screened all available family members for mutations in both VEGFR3 tyrosine kinase domains. Our screen identified a novel 3059A > T transversion in exon 22 resulting in a Q1020L missense mutation located in the second tyrosine kinase domain. The mutation segregated with lymphedema among the affected individuals of the family in an autosomal dominant manner with incomplete penetrance.
MATERIALS AND METHODS

Ascertainment
The proband was self-referred to the Stanford Center for Lymphatic and Venous Disorders for evaluation of severe, congenital, bilateral lower extremity lymphedema and moderately severe hydrocele. A family history of lymphedema in the proband's family suggested the presence of a hereditary form of lymphedema. Therefore, informed consent for examination and DNA testing was obtained from all subjects in accordance with the University of Michigan Medical School Institutional Review Board. The family members were identified by the proband and all agreed to participate in the evaluation.
Phenotypic Analysis
All participating family members had a thorough assessment of their lower extremity anatomy by one of the authors (SGR), with qualitative assessment of the presence of pitting edema, hyperkeratosis, subcutaneous thickening, and the presence or absence of Stemmer sign. The morphology of the nail plates was assessed, along with documentation of the appearance of the superficial venous vasculature. Genital examination was performed to identify or exclude the presence of hydrocele in all male family members.
DNA Isolation
Genomic DNA was extracted from 5 or 10 ml blood samples using a guanidine HCl method for DNA extraction from blood [Ciulla et al., 1988] .
VEGFR3 Sequencing
Each of the exons (exons 18-26) that encode the tyrosine kinase domains of VEGFR3 were amplified using the GC Rich PCR System (Roche, Indianapolis, IN) with following primer sets ( Table I) . Exons 23 and 25 were amplified as previously described [Evans et al., 2003] . The resulting PCR products were treated with shrimp alkaline phosphatase (Roche) and exonuclease I (USB Biologicals, Cleveland, OH) and then submitted to the University of Michigan DNA Sequencing Core (http://seqcore.brcf.med. umich.edu/) for sequence analysis.
FOXC2 Mutation Screening
FOXC2 mutation screening was performed as previously described [Fang et al., 2000] .
Multiple Sequence Alignment VEGFR3 protein sequences were retrieved from Genbank. The following Genbank sequences were aligned using ClustalW [Thompson et al., 1994] . (http://www.ebi.ac.uk/clustalw/): Homo sapiens (NP_891555.1), Canis familiaris (XP_538585.2), Mus musculus (NP_032055.1), Rattus norvegicus (XP_579569.1), and Gallus gallus (XP_414600.1). The conservation of the Q1020 was compared to other receptor tyrosine kinases including: EGFR (BAD92679), FGFR1 (AAH18128), MET (EAL24359), PDGFRB (AAH32224), RET (AAH04257).
RESULTS
The proband was evaluated for severe bilateral lower extremity lymphedema as described in Materi- als and Methods. Upon evaluation, the presence of lymphedema was confirmed, and the proband was also noted to have marked cutaneous fibrotic changes and hydrocele. The interview with the proband indicated a significant family history of lymphedema; therefore, a pedigree was ascertained ( Fig. 1 ) and blood samples were collected from 20 related individuals, representing four generations of the family. Clinical evaluations of each of the related individuals are summarized in Table II . Lower limb lymphedema was primarily bilateral (10/11) and ranged from moderate to severe. All of the affected individuals had congenital onset of lymphedema, with the exception of individual II-5 who developed lymphedema at the age of 21. In addition to lymphedema, some affected individuals displayed hyperkeratosis, ski jump toenails, varicose veins, and hydrocele (Table II) . For Milroy cases that have been rigidly defined both clinically and molecularly, each of these phenotypes has been previously reported in association with Milroy disease [Brice et al., 2005] . Possible distichiasis was noted in some of the individuals but was not verified by an ophthalmologist. Distichiasis is associated with lymphedema-distichiasis syndrome (LD), another form of inherited primary lymphedema (OMIM #153400). LD is caused by mutations in the forkhead transcription factor FOXC2 [Fang et al., 2000] . Mutational screening did not detect mutations or polymorphisms in the FOXC2 single coding exon.
Further evaluation of the pedigree demonstrated that the possible distichiasis did not segregate with lymphedema and was also reported in family members without lymphedema and thus was excluded from consideration. Since VEGFR3 mutations are known to cause some cases of Milroy disease , we screened VEGFR3 for mutations. All previously reported VEGFR3 mutations localize to one of the two tyrosine kinase domains in the cytoplasmic portion of the VEGFR3 receptor (Table III) [Irrthum et al., 2000; Karkkainen et al., 2000; Evans et al., 2003; Brice et al., 2005; Daniel-Spiegel et al., 2005; Mizuno et al., 2005; Ghalamkarpour et al., 2006; Spiegel et al., 2006] . Therefore, we amplified and sequenced VEGFR3 exons 18 through 26, which encompass both of the tyrosine kinase domains of VEGFR3. DNA sequencing revealed a novel 3059A > T transversion in exon 22 ( Fig. 2A) . Each of the affected individuals (I-1, I-5, III-13, III-15, III-17, III-18, III-21, IV-3, IV-14, IV-15, IV-16) are heterozygous for the 3059T allele (Fig. 1) . With the exception of individuals IV-6 (age 19), IV-10 (age 17), and IV-17 (age 22), each of the unaffected individuals did not inherit the 3059T allele. The 3059T allele makes a non-conservative missense mutation changing an evolutionarily conserved glutamine residue to leucine at amino acid position 1020 of VEGFR3 (Fig. 2B,C) .
DISCUSSION
We have identified a novel VEGFR3 mutation that likely causes Milroy disease in a large family. It is the first mutation reported in exon 22 of the VEGFR3 gene. Without functional data, the possibility remains that the identified change encodes a coding polymorphism. However, previous inquires by Iljin et al. [2001] and Evans et al. [2003] identified six and four polymorphisms, respectively, in the VEGFR3 coding region, none of which encoded the Q1020L missense mutation. Additionally, twelve other coding SNPs in the VEGFR3 gene (rs307821, rs307826, rs448012, rs744282, rs1049076, rs1049077, rs1049080, rs1130378, rs1130379, rs2270519, rs3736061, and rs3736062) are reported in the SNP database (NCBI) which also do not encode the Q1020L mutation.
Based upon this previous work and the available data in the SNP database, the Q1020L amino acid change does not appear to be a polymorphism.
In addition to the available variation data, segregation of the 3059T allele among all affected family members argues strongly against it being a coding region polymorphism. Although three unaffected individuals (IV-6, IV-10, and IV-17) did inherit the 3059T allele but did not develop lymphedema or any of the other clinical associations, previous clinical studies of families with Milroy disease has demonstrated incomplete penetrance. In a study of ten families, Brice et al. [2005] reported ten percent of individuals with Milroy disease mutations in VEGFR3 do not develop lymphedema which correlates with our 21 percent (3/14).
The 3059A > T mutation changes a conserved glutamine residue to leucine in the second tyrosine kinase domain causing a predicted loss or attenuation of VEGFR3 function. The replacement of glutamine with leucine introduces a nonpolar amino acid in place of a polar uncharged amino acid. Although the charge remains the same and the relative structure of the side chain is similar, the change in potential hydrogen bonding resulting from the presence of glutamine could disrupt the function of the second tyrosine kinase domain or alter the stability of the overall structure of VEGFR3. All known VEGFR3 mutations (Table III) are located in tyrosine kinase domains. Therefore, this mutation will likely result in defective VEGF-C and VEGF-D signaling due to dominant negative inhibition of VEGFR3 autophosphorylation as established by Karkkainen et al. [2000] .
Our case illustrates a novel mutation in exon 22 of VEGFR3 in the second tyrosine kinase domain. All known VEGFR3 mutations in Milroy disease have been found in the tyrosine kinase domains. It remains unclear to date whether Milroy disease or Evans et al. [2003] other variations of congenital lymphedema are caused by mutations in other domains of VEGFR3. The possibility exists that mutations that disrupt the ligand-binding function are more severe and incompatible with life. Therefore, mutational testing of the tyrosine kinase domains of VEGFR3 is a logical first step to address the molecular cause of Milroy disease.
